PDF POSTER
-
PDF POSTER
Effect of Efavirenz on
Lopinavir/ritonavir Pharmacokinetics from a new Tablet Formulation
C Klein, T Zhu, WL Chiu, et al
-
PDF POSTER
What
is the Cost of Treating a Typical HIV-Centre Patient Cohort. with either a
Kaletra Regimen
in the UK?
T Toward, G Scullard, F Pang
-
PDF POSTER
Seven
Year Follow-up of a Lopinavir/ritonavir (LPV/r)-Based Regimen in Antiretroviral
(ARV)-
Naïve Subjects
R Murphy, B daSilva, F McMillan, et al
-
PDF POSTER
Antiviral Activity of
Lopinavir/ritonavir-Based Regimens in Subjects with CD4 Cell Counts Below
25 Cells/mm3
M King, M Johnson, M Youle, et al
-
PDF POSTER
Improved Metabolic Profile with Replacement of
Stavudine by Tenofovir DF After 6 Years
of a LPV/r-Based Regimen
B da Silva, M Albrecht, C Benson, et al
-
PDF POSTER
Differences in Adverse Event Profiles in Antiretroviral-Naive Subjects
Starting Antiretroviral
Therapy with CD4 Counts <50 Cells/mm3
vs. >200 Cells/mm3:Does Immune Reconstitution
Inflammatory Syndrome (IRIS) Play a
Role?
C Fichtenbaum, WC Woodward, T Bykov, et al
-
PDF POSTER
Preclinical Evaluation of Gastrointestinal
Tolerability of HIV Protease Inhibitors in a Ferret Model
Mark A. Osinski, Thomas K. Shaughnessy, Andrew E. Rose, et al;
-
New Data Show a Kaletra® (lopinavir/ritonavir)-based
Regimen Demonstrated Continued Efficacy
and Favorable Resistance Profile
for Patients Through Seven Years of Initial HIV Therapy
Abbott Laboratories November 18. 2005
|
